Glenmark Pharmaceuticals Inc., USA (Glenmark) has announced the launch of Vancomycin Hydrochloride for Injection USP in 750 mg/vial, 1.25 g/vial, and 1.5 g/vial single-dose vials. The product is bioequivalent and therapeutically equivalent to the reference listed drug, Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial, and 1.5 g/vial, originally developed by Mylan Laboratories under NDA 209481.
Vancomycin Hydrochloride for Injection is an antibacterial drug used to treat serious bacterial infections. Glenmark’s launch of this product expands its injectable offerings in the US market.